1
|
Olmo ED, Barboza B, Delgado-Esteban M, Escala N, Jiménez-Blasco D, Lopez-Pérez JL, Cillero de la Fuente L, Quezada E, Munín J, Viña D, Bolaños JP, Feliciano AS. Potent, selective and reversible hMAO-B inhibition by benzalphthalides: Synthesis, enzymatic and cellular evaluations and virtual docking and predictive studies. Bioorg Chem 2024; 146:107255. [PMID: 38457955 DOI: 10.1016/j.bioorg.2024.107255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 02/13/2024] [Accepted: 02/29/2024] [Indexed: 03/10/2024]
Abstract
Monoaminooxidases (MAOs) are important targets for drugs used in the treatment of neurological and psychiatric disorders and particularly on Parkinson's Disease (PD). Compounds containing a trans-stilbenoid skeleton have demonstrated good selective and reversible MAO-B inhibition. Here, twenty-two (Z)-3-benzylidenephthalides (benzalphthalides, BPHs) displaying a trans-stilbenoid skeleton have been synthesised and evaluated as inhibitors of the MAO-A and MAO-B isoforms. Some BPHs have selectively inhibited MAO-B, with IC50 values ranging from sub-nM to μM. The most potent compound with IC50 = 0.6 nM was the 3',4'-dichloro-BPH 16, which showed highly selective and reversible MAO-B inhibitory activity. Furthermore, the most selective BPHs displayed a significant protection against the apoptosis, and mitochondrial toxic effects induced by 6-hydroxydopamine (6OHDA) on SH-SY5Y cells, used as a cellular model of PD. The results of virtual binding studies on the most potent compounds docked in MAO-B and MAO-A were in agreement with the potencies and selectivity indexes found experimentally. Additionally, related to toxicity risks, drug-likeness and ADME properties, the predictions found for the most relevant BPHs in this research were within those ranges established for drug candidates.
Collapse
Affiliation(s)
- Esther Del Olmo
- Departamento de Ciencias Farmacéuticas: Química Farmacéutica. Facultad de Farmacia. Universidad de Salamanca, CIETUS, IBSAL. Campus Miguel de Unamuno s/n. 37007 Salamanca, Spain.
| | - Bianca Barboza
- Departamento de Ciencias Farmacéuticas: Química Farmacéutica. Facultad de Farmacia. Universidad de Salamanca, CIETUS, IBSAL. Campus Miguel de Unamuno s/n. 37007 Salamanca, Spain
| | - Maria Delgado-Esteban
- Institute of Functional Biology and Genomics (IBFG), Universidad de Salamanca, CSIC, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain
| | - Nerea Escala
- Departamento de Ciencias Farmacéuticas: Química Farmacéutica. Facultad de Farmacia. Universidad de Salamanca, CIETUS, IBSAL. Campus Miguel de Unamuno s/n. 37007 Salamanca, Spain
| | - Daniel Jiménez-Blasco
- Institute of Functional Biology and Genomics (IBFG), Universidad de Salamanca, CSIC, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain
| | - José L Lopez-Pérez
- Departamento de Ciencias Farmacéuticas: Química Farmacéutica. Facultad de Farmacia. Universidad de Salamanca, CIETUS, IBSAL. Campus Miguel de Unamuno s/n. 37007 Salamanca, Spain; Facultad de Medicina, Universidad de Panamá, Panamá, R. de Panamá
| | - Laura Cillero de la Fuente
- Institute of Functional Biology and Genomics (IBFG), Universidad de Salamanca, CSIC, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain
| | - Elías Quezada
- Chronic Diseases Pharmacology Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela. Spain
| | - Javier Munín
- Chronic Diseases Pharmacology Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela. Spain
| | - Dolores Viña
- Chronic Diseases Pharmacology Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela. Spain.
| | - Juan P Bolaños
- Institute of Functional Biology and Genomics (IBFG), Universidad de Salamanca, CSIC, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
| | - Arturo San Feliciano
- Departamento de Ciencias Farmacéuticas: Química Farmacéutica. Facultad de Farmacia. Universidad de Salamanca, CIETUS, IBSAL. Campus Miguel de Unamuno s/n. 37007 Salamanca, Spain; Programa de Pós-graduação em Ciências Farmacéuticas, Universidade do Vale do Itajaí, UNIVALI. Itajaí, SC, Brazil
| |
Collapse
|